Aagami has received a new assignment from an existing client, to support regional/global partnering initiative for their Marketed Dental gel addressing Periodontitis, Gingivitis, & Caries.
Key Highlights:
- LivFresh is a Dental gel already approved in EU for Prevention & Treatment of Periodontitis, Gingivitis, & Caries.
- Being sold in the US in the OTC category. Livfresh US sales of 2025 closed at $40 Million, which enabled the company to profitably grow 5X from 2024 revenues.
- 2026 revenue forecast – $120 Million on a profitable basis.
- Clinically Proven to Reduce Probing Pocket Depths as well as Gingival Inflammation and Bleeding.
- Verified by 26 research studies
- ~2X-5X more effective than existing Anti-Gingivitis Toothpastes.
- Removes plaque 250% better. Improves gum health 190% more.
- Cleans teeth & heal gums on a molecular level.
- Recommended by 3,000+ dental professionals.
- Comprehensive Oral Care Patent portfolio (Valid up to 2043)
- LIVFRESH has been Featured in WSJ, FOX, NBC, ABC, GQ.
- US Prevalence of Gingivitis/Periodontitis ~200 Million people and TAM is $11.5 Billion.
- US Peak sales of LIVFRESH are estimated to be $576M at 5% market penetration.
LIVFRESH is a de-risked product & Available for Licensing/Distribution outside Japan (As commercial plan already in place), China, and core English speaking countries like US, UK, AU where the client is/will commercialize/commercializing themselves.
If you would like to know more, please contact us on action@aagami.com.